Effect of Secukinumab in the Treatment of Psoriatic Arthritis
Status:
Completed
Trial end date:
2019-09-18
Target enrollment:
Participant gender:
Summary
The investigators propose an open label pragmatic clinical and laboratory study designed to
investigate, in detail, the clinical and molecular effects of Interleukin 17 (IL-17) and
inhibition of IL-17 with secukinumab, on neutrophil function in vitro and ex vivo.
As secondary, exploratory objectives, the investigators will utilise the fact that
secukinumab is to be administering to 20 patients with Psoriatic Arthritis (PsA) and
investigate whether there is any relationship between vitamin D status and response to
secukinumab, with respect to efficacy and adverse events. The results of this secondary
exploratory analysis will inform the design of a larger, definitive study.